Recommendations for User Fee Programs: Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 Through 2017; Meeting
Title: Pfizer Inc PFE Comments FDA 2011-N-0326
Pfizer Inc - Comment
This is comment on Notice
Recommendations for User Fee Programs: Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 Through 2017; Meeting
View Comment
Attachments:
Pfizer Inc PFE Comments FDA 2011-N-0326
Title:
Pfizer Inc PFE Comments FDA 2011-N-0326
Related Comments
View AllPublic Submission Posted: 01/11/2012 ID: FDA-2011-N-0326-0026
Jan 06,2012 11:59 PM ET
Public Submission Posted: 01/11/2012 ID: FDA-2011-N-0326-0027
Jan 06,2012 11:59 PM ET
Public Submission Posted: 01/11/2012 ID: FDA-2011-N-0326-0028
Jan 06,2012 11:59 PM ET
Public Submission Posted: 01/11/2012 ID: FDA-2011-N-0326-0032
Jan 06,2012 11:59 PM ET
Public Submission Posted: 01/11/2012 ID: FDA-2011-N-0326-0034
Jan 06,2012 11:59 PM ET